INCATE is for innovators fighting drug-resistant bacterial infections with new therapies, development platforms, diagnostics, digital tools and supporting technologies. We want to help you to build investable projects and companies that are ready for the next level of investment from Industry, targeted funds like Carb-X or Novo Repair fund, traditional investors and in some cases further non-dilutive funding. As of Q1 2022 our focus is on therapies and we are investigating how we can help with diagnostics and devices. Digital tools are not likely to be considered until late 2022 at the earliest (unless you wow us). To give you an idea of approximate stage, we think we can help most in the following space; Drug projects with initial proof of concept and hit/lead identified- (TRL 2-4) Diagnostic projects that have a POC (TRL 3-4) Digital tools and other technologies that have a POC from one setting, though the nature of these innovations means it may be harder to set a clear boundary(TRL 3-5) If you aren’t sure please contact us.

INCubator for Antimicrobial
Therapies in Europe

What if I receive significant funding during the program?

Q: What if I receive significant funding during the program?

That is great and what we are all working towards. You can choose to continue to work with INCATE but funding from INCATE may no longer be relevant.

Q: Am I obliged to give equity?

No. The advice and funding is provided at no-cost and with no dilution.

Q: Am I obliged to work with your Industry Partners?

No. We hope that you are able to find a fruitful collaboration with Partners in our network but there is no obligation to do so.

Q: What obligations do I have to INCATE after receiving support?

We hope you continue to support INCATE post the program as part of the community. There is no obligation to give back. As the business model for Antibiotics is fixed and the reward for Antibiotic innovators increase in coming years we hope that you would re-invest in the next generation of Antibiotics.

Q: What happens after INCATE Stage II?

We hope that during Stage II you are able to produce enough evidence to get support from other members of the ecosystem supporting the fight against drug-resistant bacterial infections such as the Industry Partners in the INCATE Selection Committee, Carb-X, GARDP, non-dilutive funding or equity investment.

Q: How do you select projects?

We try and support all early stage innovators with advice from INCATE management and access to our community and events. As part of this we help you prepare an application to the INCATE Selection Committee for acceptance in to Stage I. We may also give you the feedback at this stage that you are not ready for Stage I and why. Stage I - The INCATE Selection Committee selects projects to be selected into Stage I. We may also invite you to discuss your venture in more detail with the INCATE Selection Committee or their representatives. We will publish a more detailed criteria over time but this is likely to include; Medical need targeted, innovation potential, likelihood of equitable access, team (a weak team is not a killer at Stage I but you need to build it!), Likelihood to develop a case for significant investment case within 24 months and our ability to help Stage II - The committee will decide which ventures are taken into Stage II and the amount of funding based on the above criteria plus progress made.

Previous 12

What if I receive significant funding during the program?

Newsletter

Contact form

Follow us